| 0 (0%) | 02-10 06:24 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31  |
1-year : | 36.21 |
| Resists | First : | 26.54 |
Second : | 31 |
| Pivot price | 26.38 |
|||
| Supports | First : | 25.65 |
Second : | 25.11 |
| MAs | MA(5) : | 26.46  |
MA(20) : | 26.36 |
| MA(100) : | 26.16 |
MA(250) : | 25.5 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 82.7 |
D(3) : | 84.5 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 26.54 | Low : | 24.45 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AJAN ] has closed below upper band by 33.9%. Bollinger Bands are 81.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.59 - 26.74 | 26.74 - 26.87 |
| Low: | 26.06 - 26.26 | 26.26 - 26.44 |
| Close: | 26.18 - 26.46 | 26.46 - 26.72 |
Sat, 08 Feb 2025
Roquefort Therapeutics sells Lyramid for $10.8mln - ICYMI - Proactive financial news
Mon, 03 Feb 2025
Roquefort Therapeutics CEO Ajan Reginald on strategic asset sale to Pleiades Pharma - Proactive Investors Australia
Thu, 30 Jan 2025
Where are the Opportunities in (AJAN) - Stock Traders Daily
Mon, 20 Jan 2025
(AJAN) Investment Analysis and Advice - Stock Traders Daily
Thu, 09 Jan 2025
When (AJAN) Moves Investors should Listen - Stock Traders Daily
Thu, 24 Oct 2024
Financial assistance is requested for Ajan Selman's recovery - Telegrafi
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|